PT  - JOURNAL ARTICLE
AU  - Giuseppe Rossoni
AU  - Monica Gomaraschi
AU  - Ferruccio Berti
AU  - Cesare R. Sirtori
AU  - Guido Franceschini
AU  - Laura Calabresi
TI  - Synthetic High-Density Lipoproteins Exert Cardioprotective Effects in Myocardial Ischemia/Reperfusion Injury
AID  - 10.1124/jpet.103.057141
DP  - 2004 Jan 01
TA  - Journal of Pharmacology and Experimental Therapeutics
PG  - 79--84
VI  - 308
IP  - 1
4099  - http://jpet.aspetjournals.org/content/308/1/79.short
4100  - http://jpet.aspetjournals.org/content/308/1/79.full
SO  - J Pharmacol Exp Ther2004 Jan 01; 308
AB  - Human high-density lipoproteins (HDLs) protect the heart against ischemia/reperfusion injury. In the present study, the cardioprotective effects of synthetic high-density lipoproteins (sHDLs) made of phosphatidylcholine and apolipoprotein A-I were investigated in isolated rat hearts, which underwent a 20-min low-flow ischemia followed by a 30-min reperfusion. The administration of sHDL during the 10 min immediately before ischemia caused a rapid, dose-dependent improvement of postischemic cardiac function: at the maximum dose (2.0 mg of sHDL protein/ml), left ventricular developed pressure (LVDP) recovered to 71.0 ± 3.2 versus 40.5 ± 3.8 mm Hg in salinetreated hearts, and coronary perfusion pressure (CPP) increased to 100.3 ± 6.2 versus 132.0 ± 9.0 mm Hg. The preservation of postischemic cardiac function was associated with a dose-dependent reduction of creatine kinase release into the coronary effluent. sHDLs administered in the first 10 min postischemia also exerted a significant, dose-dependent improvement of postischemic LVDP, CPP, and creatine kinase release, but the cardioprotective effect was less than when sHDLs were given preischemia. The preservation of postischemic cardiac function by sHDL was mediated through a reduction of cardiac tumor necrosis factor-α content and an enhanced cardiac production of prostaglandin E2 and I2. The present experimental data indicate that sHDLs may provide a novel therapeutic approach to clinical conditions in which myocardial ischemia/reperfusion occurs, such as acute coronary syndromes, cardiac surgery, or revascularization procedures. The American Society for Pharmacology and Experimental Therapeutics